Therapeutic innovation in the dermatology space is growing at an exponential rate, propelling an increase in the awareness and knowledge of inflammatory skin conditions’ pathophysiology. The summit will tackle issues and focus on the optimization of novel strategies to accelerate the development and commercialization of dermatological treatments for chronic inflammatory and autoimmune skin conditions.

The summit will cover various topics, the including regulatory perspective of the current dermatology drug development landscape, discovery, pre-clinical development and translational research, clinical development and research as well as market access, reimbursement and commercial decision making.

We are delighted to say that SCARLETRED will be joining as an innovation partner and as part of the summit, our CEO, Dr. Harald Schnidar, will be among the great speakers giving insights into “Artificial Intelligence Supported Mobile Skin Imaging & Objective Digital Analysis of Drug Effects in Clinical Trials & Post-Marketing”.

‍

Visit the official homepage of the 3rd Annual Dermatology Drug Development Europe Summit to explore more about the event.